Orris

Describe the epidemiology of polio myelitis in India. Explain the strategy of polio eradication in India. Add a note on the use of monovalent and bivalent vaccines. Discuss on the measures undertaken to eradicate polio myelitis globally.

Reading File
Finding Sources
Finding Sources
Searching the Web

polio eradication India epidemiology strategy pulse polio monovalent bivalent vaccine

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
I now have enough content from Park's textbook covering the epidemiology, strategies, vaccines, and surveillance. I have comprehensive data from both the textbook and web sources. Let me now compile the complete answer.

Poliomyelitis: Epidemiology, Eradication in India, and Global Measures

(Based primarily on Park's Textbook of Preventive and Social Medicine)

1. Epidemiology of Poliomyelitis in India

The Disease

Poliomyelitis is an acute viral infection caused by an RNA virus (enterovirus). It is primarily an infection of the human alimentary tract, but the virus may invade the central nervous system in approximately 1% of cases, resulting in varying degrees of flaccid paralysis and possibly death.

Global Context

In the pre-vaccination era, poliomyelitis was found in all countries of the world. The extensive use of polio vaccines since 1954 eliminated the disease in developed countries. In 1988, the World Health Assembly (WHA) resolved to eradicate poliomyelitis globally. Since then, implementation of eradication strategies reduced the number of polio-endemic countries from more than 125 in 1988 to just 3 in 2017 (Afghanistan, Pakistan, and Nigeria).

Epidemiology in India

India was one of the largest reservoirs of wild poliovirus in the world, with hundreds of thousands of paralytic cases annually before vaccination programmes began. Key epidemiological features in India included:
  • High-risk geography: The states of Uttar Pradesh (UP) and Bihar were the most persistently endemic areas, owing to large populations, poor sanitation, dense crowding, high birth rates, open defecation, and a high concentration of immunocompromised children due to malnutrition and concurrent diarrheal illnesses - factors that reduced vaccine efficacy.
  • Age distribution: The disease predominantly affected children under 5 years of age, peaking in the 1-4 year age group.
  • Seasonality: Transmission peaks from June to September (monsoon/summer), so Pulse Polio Immunization (PPI) rounds were strategically scheduled between November and February (low transmission season).
  • Serotype distribution: Wild poliovirus type 1 (WPV1) was the major cause of paralytic disease in India, while WPV3 was also circulating. WPV2 was last detected in India in the early 1990s.
  • Declining trend: Following the National Immunization Days (NIDs) started in 1995-96, cases fell dramatically. The last case of wild polio in India was reported from Howrah, West Bengal, with disease onset on 13 January 2011. On 27 March 2014, India was officially declared a non-endemic (polio-free) country by WHO.
  • Surveillance indicator: AFP (Acute Flaccid Paralysis) reporting increased from 1,005 cases in 1996 to 11,675 cases by 2020 - not a rise in disease but a reflection of vastly improved surveillance. Stool specimen collection completeness improved from 59% (1998) to 82% (2020).

2. Strategy of Polio Eradication in India

The Government of India adopted a multi-pronged strategy to eradicate poliomyelitis, as outlined below:

(a) Pulse Polio Immunization (PPI) / National Immunization Days (NIDs)

The Government of India conducted the first round of PPI on 9 December 1995 and 20 January 1996 (two rounds 6 weeks apart), targeting all children under 3 years of age regardless of previous immunization status. The age group was later extended to under 5 years as per WHO recommendation.
The term "pulse" describes the sudden, simultaneous, mass administration of OPV on a single day to all children 0-5 years of age. PPI rounds occur as two rounds approximately 4-6 weeks apart during the low transmission season (November to February). PPI doses supplement but do not replace routine immunization doses.

(b) Routine Immunization (RI)

Sustained high levels of routine immunization coverage were maintained so that every child completed the OPV schedule. The OPV doses given during PPI are extra doses and do not replace scheduled RI doses.

(c) AFP Surveillance

  • All cases of Acute Flaccid Paralysis (AFP) in children under 15 years are mandatorily reported.
  • Active AFP surveillance was extended from polio alone to all causes of AFP since 1992.
  • A network of Surveillance Medical Officers (SMOs) - specially trained personnel responsible for defined areas - was established. A national surveillance team is positioned in Delhi.
  • A regular weekly reporting system is in place.
  • Line listing of reported cases started in 1989 to check for duplication, identify high-risk pockets, and document high-risk age groups.

(d) Case Investigation and Outbreak Response

  • Rapid case investigation including collection of two stool samples for virus isolation is mandatory.
  • Even a single case is treated as an outbreak, and preventive measures are initiated within 48 hours of notification.
  • All AFP cases receive a 60-day follow-up to assess for residual paralysis.
  • During an epidemic, OPV is provided to all persons over 6 weeks of age who have not been completely immunized.

(e) Mopping Up

Mopping up is the last stage in eradication. It involves door-to-door immunization in high-risk districts where wild poliovirus is known or suspected to still circulate. This strategy was actively implemented in UP, Bihar, and other high-risk areas.

(f) Sub-National Immunization Days (SNIDs)

Targeted immunization campaigns in high-risk districts, especially in UP and Bihar, supplemented national campaigns.

(g) Intensified Strategies in High-Risk Areas (2005-2006 onwards)

Following recommendations from the India Expert Advisory Group on Polio Eradication (IEAG):
  • Development and licensure of monovalent OPV1 (mOPV1) and mOPV3 for targeted use during SIAs based on surveillance data.
  • Deployment of additional personnel to assist with intensified SIAs in Bihar, UP, and Mumbai.
  • Use of mobile teams to vaccinate children at transit points - railway stations, bus stations, and moving trains.
  • Special booths at international borders (e.g., Wagah border, Attari station, Munabo station in Rajasthan) to ensure children coming from neighboring countries receive polio drops.
  • A specific recommendation (May 2006) to identify and give a "birth dose" of mOPV1 to all neonates in high-risk areas of UP.

(h) Monitoring and Quality Assurance

  • Vaccine Vial Monitors (VVM): Colour-coded labels on vaccine bottles indicating heat exposure. Made mandatory in all vaccine procurements since 1998.
  • OPV coverage monitored at district level and below.
  • 107 high-risk blocks identified for multi-pronged strategy including sanitation, hygiene, clean drinking water, alongside vaccination.

(i) Polio Endgame Measures in India

  • IPV introduction: India introduced Inactivated Polio Vaccine (IPV) in the national immunization programme from 30 November 2015.
  • tOPV to bOPV switch: On 25 April 2016 (National Switch Day), India switched from trivalent OPV (tOPV) to bivalent OPV (bOPV), withdrawing all tOPV from the cold chain.
  • Rapid Response Teams (RRTs): All states and union territories developed RRTs and Emergency Preparedness and Response Plans (EPRPs).
  • Environmental surveillance continues at multiple sites to detect poliovirus in sewage.
  • Rolling emergency OPV stock maintained to respond to any WPV or cVDPV detection.

3. Note on Monovalent and Bivalent Vaccines

Trivalent OPV (tOPV)

The original oral polio vaccine contained all three serotypes (types 1, 2, and 3). While effective, competition between the three strains for gut replication in areas with high diarrheal burden (like UP and Bihar) reduced the immune response to each individual type.

Monovalent OPV (mOPV)

When type-specific outbreaks occurred, monovalent OPVs (mOPV1 and mOPV3) were developed and licensed in 2005-2006. Each contains only one serotype.
Advantages of mOPV over tOPV:
  • Higher seroconversion rates for the targeted serotype because there is no competition between strains.
  • In areas of India where WPV1 was dominant, mOPV1 gave significantly better protection per dose than tOPV.
  • The IEAG prioritized mOPV1 in 2006 to control WPV1 in UP and Bihar, accepting a transient increased risk from WPV3, which was believed to be easier to eliminate subsequently.
Operational challenge: Giving mOPV1 and mOPV3 simultaneously raised concerns about whether co-administration would compromise efficacy of each, and added complexity for 2.3 million vaccinators accustomed to giving a single vial.

Bivalent OPV (bOPV)

Following the global declaration that WPV2 had been eradicated (last detected in 1999), the Global Polio Eradication Initiative (GPEI) recommended a globally synchronized switch from tOPV to bivalent OPV (bOPV), containing only types 1 and 3, to eliminate the risk of vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived poliovirus type 2 (cVDPV2). The type 2 component of tOPV caused more than 90% of VDPVs and nearly 40% of VAPP cases.
India completed this switch in April 2016. Alongside the switch:
  • IPV was introduced to maintain immunity against type 2, since bOPV no longer covers it.
  • IPV is recommended at 14 weeks (with the 3rd dose of pentavalent vaccine), or as a fractional dose IPV (fIPV) given intradermally at 6 and 14 weeks (2 doses of 0.1 mL each by intradermal route), which studies showed provides higher seroconversion than a single full dose IM.
The current GPEI strategy (2022-2026) includes a plan for bOPV cessation and eventual transition to IPV-only schedules once WPV1 and WPV3 are certified eradicated globally.

4. Global Measures to Eradicate Poliomyelitis

The Global Polio Eradication Initiative (GPEI)

Launched in 1988 following the WHA resolution, the GPEI is a public-private partnership led by national governments, WHO, Rotary International, the US CDC, UNICEF, and the Bill & Melinda Gates Foundation. It represents the largest internationally coordinated public health effort in history.

Key Global Strategies

1. Routine Immunization (RI) All countries are required to include OPV in their expanded programme on immunization (EPI), ensuring every child receives at least 3 doses in infancy.
2. National Immunization Days (NIDs) Mass campaigns targeting all children under 5 regardless of vaccination history, conducted twice per year during low transmission seasons. In India alone, these campaigns covered over 170 million children per round.
3. Supplementary Immunization Activities (SIAs) Additional campaigns targeting high-risk areas and populations - migrants, nomads, displaced persons, and communities with vaccine refusal.
4. AFP Surveillance A global system for detecting, reporting, investigating, and responding to AFP cases. Under the International Health Regulations, polio is subject to international surveillance. WHO must be notified promptly of any paralytic polio case, and quarterly reports on prescribed forms are submitted to WHO Geneva.
5. Mopping Up Door-to-door immunization in areas where wild poliovirus is still thought to be circulating.
6. OPV Withdrawal and IPV Introduction The global switch from tOPV to bOPV was completed in April 2016, and at least one dose of IPV was introduced in all routine immunization schedules globally to protect against type 2 poliovirus.
7. Containment After WPV2 eradication, all laboratory stocks of WPV2 must be either destroyed or transferred to approved containment facilities. This is critical to prevent accidental release.
8. Environmental Surveillance Testing of sewage/wastewater samples for poliovirus allows detection of silent transmission before clinical cases appear.
9. Vaccine-Derived Poliovirus (cVDPV) Response Outbreak response immunization (ORI) using mOPV2 (in type 2 outbreaks) and mOPV1/3 for respective serotypes.

Current Status (as of 2026)

  • WPV2 was declared eradicated globally in 2015.
  • WPV3 was declared eradicated globally in 2019.
  • WPV1 remains endemic only in Afghanistan and Pakistan.
  • cVDPV outbreaks continue to pose a challenge in several countries with low routine immunization coverage.
  • The GPEI Endgame Strategy 2022-2026 focuses on: interrupting WPV1 in the remaining endemic countries, stopping cVDPV transmission globally, and transitioning to government-led, IPV-based immunization after OPV withdrawal.
Source: Park's Textbook of Preventive and Social Medicine, Chapter on Poliomyelitis (Section II: Intestinal Infections), pp. 240-248; supplemented by PIB India press release on polio eradication milestones and GPEI Endgame Strategy 2022-2026.

Make pdf

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && ls -la /tmp/workspace/

Running Command

mkdir -p /tmp/workspace/polio-pdf && cat > /tmp/workspace/polio-pdf/generate_pdf.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm from reportlab.lib import colors from reportlab.platypus import ( SimpleDocTemplate, Paragraph, Spacer, HRFlowable, ListFlowable, ListItem, Table, TableStyle, KeepTogether ) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY OUTPUT = "/tmp/workspace/polio-pdf/Poliomyelitis_India_Eradication.pdf" doc = SimpleDocTemplate( OUTPUT, pagesize=A4, leftMargin=2.5*cm, rightMargin=2.5*cm, topMargin=2.5*cm, bottomMargin=2.5*cm, title="Poliomyelitis: Epidemiology & Eradication in India", author="Orris Medical Assistant" ) styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle( 'CustomTitle', parent=styles['Title'], fontSize=18, textColor=colors.HexColor('#1a3a5c'), spaceAfter=6, spaceBefore=0, alignment=TA_CENTER, fontName='Helvetica-Bold' ) subtitle_style = ParagraphStyle( 'Subtitle', parent=styles['Normal'], fontSize=11, textColor=colors.HexColor('#4a6fa5'), spaceAfter=18, alignment=TA_CENTER, fontName='Helvetica' ) h1_style = ParagraphStyle( 'H1', parent=styles['Heading1'], fontSize=13, textColor=colors.white, backColor=colors.HexColor('#1a3a5c'), spaceBefore=16, spaceAfter=8, leftIndent=-0.5*cm, rightIndent=-0.5*cm, leading=20, fontName='Helvetica-Bold', borderPad=5 ) h2_style = ParagraphStyle( 'H2', parent=styles['Heading2'], fontSize=11, textColor=colors.HexColor('#1a3a5c'), spaceBefore=10, spaceAfter=4, fontName='Helvetica-Bold', borderPad=2, borderColor=colors.HexColor('#4a6fa5'), borderWidth=0, leftIndent=0, borderRadius=2 ) h3_style = ParagraphStyle( 'H3', parent=styles['Heading3'], fontSize=10, textColor=colors.HexColor('#2c5f8a'), spaceBefore=8, spaceAfter=3, fontName='Helvetica-Bold', ) body_style = ParagraphStyle( 'Body', parent=styles['Normal'], fontSize=9.5, leading=14, spaceAfter=6, alignment=TA_JUSTIFY, fontName='Helvetica' ) bullet_style = ParagraphStyle( 'Bullet', parent=body_style, leftIndent=14, bulletIndent=0, spaceAfter=3, ) note_style = ParagraphStyle( 'Note', parent=body_style, fontSize=8.5, textColor=colors.HexColor('#555555'), leftIndent=10, rightIndent=10, backColor=colors.HexColor('#f0f4f8'), borderPad=6, borderColor=colors.HexColor('#4a6fa5'), borderWidth=1, borderRadius=3 ) story = [] # ── TITLE ────────────────────────────────────────────────────────────────── story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("Poliomyelitis", title_style)) story.append(Paragraph( "Epidemiology in India | Eradication Strategy | Monovalent &amp; Bivalent Vaccines | Global Measures", subtitle_style )) story.append(HRFlowable(width="100%", thickness=2, color=colors.HexColor('#1a3a5c'), spaceAfter=10)) story.append(Paragraph("Source: Park's Textbook of Preventive and Social Medicine | Orris Medical", note_style)) story.append(Spacer(1, 0.4*cm)) # ── SECTION 1 ────────────────────────────────────────────────────────────── story.append(Paragraph("1. Epidemiology of Poliomyelitis in India", h1_style)) story.append(Paragraph("<b>The Disease</b>", h3_style)) story.append(Paragraph( "Poliomyelitis is an acute viral infection caused by an RNA enterovirus. It is primarily an " "infection of the human alimentary tract, but the virus may invade the central nervous system " "in approximately <b>1% of cases</b>, resulting in varying degrees of flaccid paralysis and possibly " "death.", body_style )) story.append(Paragraph("<b>Global Context</b>", h3_style)) story.append(Paragraph( "In the pre-vaccination era, poliomyelitis was found in all countries. Widespread use of polio " "vaccines since 1954 eliminated the disease in developed countries. In 1988, the World Health " "Assembly (WHA) resolved to eradicate poliomyelitis globally - reducing endemic countries from " "<b>more than 125 in 1988</b> to just <b>3 in 2017</b> (Afghanistan, Pakistan, Nigeria).", body_style )) story.append(Paragraph("<b>Epidemiology in India</b>", h3_style)) bullets_epi = [ "<b>High-risk geography:</b> Uttar Pradesh (UP) and Bihar were the most persistently endemic states - large populations, poor sanitation, crowding, high birth rates, open defecation, and malnutrition reducing vaccine efficacy.", "<b>Age distribution:</b> Predominantly children under 5 years, peaking in the 1-4 year age group.", "<b>Seasonality:</b> Transmission peaks June-September (monsoon); PPI rounds scheduled November-February (low transmission season).", "<b>Serotype distribution:</b> Wild poliovirus type 1 (WPV1) was the dominant cause of paralytic disease. WPV3 also circulated. WPV2 was last detected in India in the early 1990s.", "<b>Last case:</b> Howrah, West Bengal - onset <b>13 January 2011</b>. India declared polio-free on <b>27 March 2014</b>.", "<b>Surveillance indicator:</b> AFP reporting rose from 1,005 cases (1996) to 11,675 (2020) - reflecting improved surveillance, not more disease. Stool specimen completeness improved from 59% (1998) to 82% (2020).", ] for b in bullets_epi: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.2*cm)) # ── SECTION 2 ────────────────────────────────────────────────────────────── story.append(Paragraph("2. Strategy of Polio Eradication in India", h1_style)) # Sub-sections subs2 = [ ( "(a) Pulse Polio Immunization (PPI) / National Immunization Days (NIDs)", "The Government of India conducted the <b>first PPI round on 9 December 1995</b> and <b>20 January 1996</b> (two rounds 6 weeks apart), initially targeting children under 3 years, later extended to under 5 years. " "'Pulse' describes the sudden, simultaneous, mass administration of OPV on a single day to all children 0-5 years regardless of previous immunization. " "PPI doses supplement but do NOT replace routine immunization doses. Two rounds are held 4-6 weeks apart each year.", ), ( "(b) Sustain Routine Immunization (RI)", "High levels of routine OPV coverage were maintained to ensure every child completed the standard schedule. " "Coverage monitored at district level and below.", ), ( "(c) AFP Surveillance", "Reporting of all AFP cases in children under 15 years is mandatory. Active AFP surveillance extended to all AFP causes (not just polio) since 1992. " "A network of <b>Surveillance Medical Officers (SMOs)</b> covers defined areas, with a national team in Delhi and regular weekly reporting.", ), ( "(d) Case Investigation and Outbreak Response", "Rapid case investigation with collection of two stool samples for virus isolation. " "<b>Even a single case is treated as an outbreak</b>, with preventive measures initiated within 48 hours. " "All AFP cases are followed up at 60 days to assess residual paralysis.", ), ( "(e) Mopping Up", "Door-to-door immunization in high-risk districts where wild poliovirus is suspected to still circulate - the final stage of eradication. Actively implemented in UP, Bihar, and other high-risk areas.", ), ( "(f) Sub-National Immunization Days (SNIDs)", "Targeted campaigns in high-risk districts of UP and Bihar supplemented national rounds. " "Migratory children from UP/Bihar tracked and vaccinated in states of Punjab, Haryana, Gujarat, and West Bengal.", ), ( "(g) Intensified Strategies (2005-2006 onwards)", "Per IEAG recommendations: (i) Monovalent OPV1/OPV3 for targeted SIAs; (ii) Additional personnel deployed to Bihar, UP, and Mumbai; (iii) Social mobilization targeting missed groups; (iv) Mobile teams at transit points - railway/bus stations, moving trains; (v) Special booths at international borders (Wagah, Attari, Munabo); (vi) Birth dose of mOPV1 for neonates in high-risk UP areas.", ), ( "(h) Monitoring and Quality Assurance", "<b>Vaccine Vial Monitors (VVMs)</b> made mandatory since 1998 - colour labels detect heat-compromised vaccines. " "107 high-risk blocks identified for multi-pronged strategy (sanitation, hygiene, clean water + vaccination).", ), ( "(i) Polio Endgame Measures", "<b>IPV introduced</b> in national immunization programme from <b>30 November 2015</b>. " "<b>tOPV to bOPV switch</b> on <b>25 April 2016 (National Switch Day)</b>. " "Rapid Response Teams (RRTs) and Emergency Preparedness and Response Plans (EPRPs) established in all states. " "Environmental surveillance at multiple sewage sites. Rolling emergency OPV stock maintained.", ), ] for title, content in subs2: story.append(Paragraph(title, h2_style)) story.append(Paragraph(content, body_style)) # ── SECTION 3 ────────────────────────────────────────────────────────────── story.append(Paragraph("3. Monovalent and Bivalent Vaccines", h1_style)) story.append(Paragraph("Trivalent OPV (tOPV)", h2_style)) story.append(Paragraph( "The original OPV contained all three serotypes (types 1, 2, 3). Effective overall, but in areas " "with high diarrheal burden (like UP and Bihar), competition between strains for gut replication " "reduced the immune response to each individual type.", body_style )) story.append(Paragraph("Monovalent OPV (mOPV1 and mOPV3)", h2_style)) story.append(Paragraph( "Developed and licensed in <b>2005-2006</b>. Each contains only one serotype, eliminating inter-strain " "competition and yielding higher seroconversion rates per dose.", body_style )) story.append(Paragraph("<b>Advantages over tOPV:</b>", h3_style)) for b in [ "Higher seroconversion for the targeted serotype (no inter-serotype competition).", "In UP/Bihar where WPV1 dominated, mOPV1 gave significantly better protection per dose.", "IEAG (2006) prioritized mOPV1 to control WPV1, accepting transient WPV3 risk (WPV3 outbreaks followed in 2007 and 2009 but were ultimately controlled).", "A specific 'birth dose' of mOPV1 was recommended for all neonates in high-risk UP areas.", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Paragraph( "<b>Operational challenge:</b> Giving mOPV1 and mOPV3 simultaneously raised concerns about efficacy " "when co-administered, and added complexity for 2.3 million vaccinators used to a single vial per child.", body_style )) story.append(Paragraph("Bivalent OPV (bOPV - Types 1 and 3)", h2_style)) story.append(Paragraph( "After global declaration that WPV2 was eradicated (last detected 1999), GPEI recommended a " "globally synchronized switch from tOPV to <b>bivalent OPV (bOPV)</b> - containing only types 1 and 3 " "- to eliminate vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived poliovirus " "type 2 (cVDPV2). The type 2 component of tOPV caused <b>&gt;90% of VDPVs</b> and <b>~40% of VAPP cases</b>.", body_style )) story.append(Paragraph("India completed this switch on <b>25 April 2016</b>.", body_style)) story.append(Paragraph("<b>Alongside bOPV switch:</b>", h3_style)) for b in [ "IPV introduced at 14 weeks (with 3rd pentavalent dose) to maintain type 2 immunity.", "Fractional dose IPV (fIPV): 2 doses of 0.1 mL intradermally at 6 and 14 weeks - higher seroconversion than single full-dose IM IPV.", "GPEI Strategy 2022-2026 includes a bOPV cessation plan and eventual transition to IPV-only schedules.", ]: story.append(Paragraph(f"• {b}", bullet_style)) # IPV comparison table story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("IPV vs. Fractional IPV (fIPV) Comparison", h2_style)) table_data = [ ["Parameter", "IPV (Full Dose)", "Fractional IPV (fIPV)"], ["Volume per dose", "0.5 mL", "0.1 mL"], ["Schedule", "1 dose at 14 weeks", "2 doses: 6 and 14 weeks"], ["Route", "Intramuscular (IM)", "Intradermal (ID)"], ["Seroconversion", "Standard", "Higher (2-dose schedule)"], ] t = Table(table_data, colWidths=[4.5*cm, 5*cm, 5*cm]) t.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a3a5c')), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ('FONTSIZE', (0,0), (-1,-1), 9), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#f0f4f8'), colors.white]), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#aaaaaa')), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('ALIGN', (0,0), (-1,-1), 'CENTER'), ('TOPPADDING', (0,0), (-1,-1), 5), ('BOTTOMPADDING', (0,0), (-1,-1), 5), ('FONTNAME', (0,1), (0,-1), 'Helvetica-Bold'), ('TEXTCOLOR', (0,1), (0,-1), colors.HexColor('#1a3a5c')), ])) story.append(t) story.append(Spacer(1, 0.3*cm)) # ── SECTION 4 ────────────────────────────────────────────────────────────── story.append(Paragraph("4. Global Measures to Eradicate Poliomyelitis", h1_style)) story.append(Paragraph( "The <b>Global Polio Eradication Initiative (GPEI)</b>, launched in 1988, is led by national governments, " "WHO, Rotary International, the US CDC, UNICEF, and the Bill &amp; Melinda Gates Foundation - the largest " "internationally coordinated public health effort in history.", body_style )) global_measures = [ ("1. Routine Immunization (RI)", "All countries include OPV in EPI, ensuring every child receives at least 3 doses in infancy. " "Strengthening RI is necessary to maintain high population immunity, especially after OPV withdrawal."), ("2. National Immunization Days (NIDs)", "Mass campaigns targeting all children under 5 regardless of vaccination history, conducted twice yearly " "during low transmission seasons. India's NIDs covered over 170 million children per round."), ("3. Supplementary Immunization Activities (SIAs)", "Additional campaigns targeting high-risk populations - migrants, nomads, displaced persons, and " "communities with vaccine hesitancy."), ("4. AFP Surveillance", "Global system for detecting, reporting, and responding to AFP cases. Under International Health " "Regulations, polio is subject to international surveillance. WHO must be notified promptly; quarterly " "reports submitted on prescribed forms to WHO Geneva."), ("5. Mopping Up", "Door-to-door immunization in areas where wild poliovirus is still thought to circulate - the final " "push in each region before certification."), ("6. OPV Withdrawal and IPV Introduction", "Global tOPV to bOPV switch completed April 2016. At least one dose of IPV introduced in all routine " "immunization schedules globally to maintain type 2 protection."), ("7. Containment", "After WPV2 eradication, all laboratory stocks of WPV2 must be destroyed or transferred to approved " "containment facilities. Within two weeks of national switch date, ministries confirmed tOPV withdrawal."), ("8. Environmental Surveillance", "Testing sewage/wastewater samples for poliovirus allows detection of silent transmission before " "clinical cases appear - a critical early-warning system."), ("9. cVDPV Outbreak Response", "Outbreak response immunization (ORI) using mOPV2 (type 2 outbreaks) or mOPV1/mOPV3 for respective " "serotypes in affected countries with low routine immunization coverage."), ] for title, content in global_measures: story.append(Paragraph(title, h2_style)) story.append(Paragraph(content, body_style)) # Status Box story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("Current Global Status (2026)", h2_style)) status_data = [ ["Poliovirus Type", "Status", "Remaining Endemic Countries"], ["WPV Type 2", "Eradicated (2015)", "None"], ["WPV Type 3", "Eradicated (2019)", "None"], ["WPV Type 1", "Endemic", "Afghanistan, Pakistan"], ["cVDPV", "Ongoing outbreaks", "Multiple low-coverage countries"], ] ts = Table(status_data, colWidths=[4.5*cm, 4*cm, 6*cm]) ts.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a3a5c')), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ('FONTSIZE', (0,0), (-1,-1), 9), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#f0f4f8'), colors.white]), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#aaaaaa')), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('ALIGN', (0,0), (-1,-1), 'CENTER'), ('TOPPADDING', (0,0), (-1,-1), 5), ('BOTTOMPADDING', (0,0), (-1,-1), 5), ('FONTNAME', (0,1), (0,-1), 'Helvetica-Bold'), ('TEXTCOLOR', (0,3), (-1,3), colors.HexColor('#cc4400')), # WPV1 row - red ('BACKGROUND', (0,3), (-1,3), colors.HexColor('#fff0ed')), ])) story.append(ts) # Footer note story.append(Spacer(1, 0.5*cm)) story.append(HRFlowable(width="100%", thickness=1, color=colors.HexColor('#cccccc'), spaceAfter=6)) story.append(Paragraph( "<b>Source:</b> Park's Textbook of Preventive and Social Medicine (Chapter on Poliomyelitis, pp. 240-248) | " "WHO Weekly Epidemiological Records | GPEI Endgame Strategy 2022-2026 | PIB India", note_style )) # Build PDF doc.build(story) print(f"PDF created: {OUTPUT}") PYEOF python /tmp/workspace/polio-pdf/generate_pdf.py

Your PDF is ready. Here is the download link:

Poliomyelitis India Eradication

PDF Document · PDF

The PDF includes all four sections from the previous answer:
  1. Epidemiology of Poliomyelitis in India - disease overview, global context, India-specific data
  2. Strategy of Polio Eradication in India - PPI, AFP surveillance, mopping up, intensified strategies, endgame measures
  3. Monovalent and Bivalent Vaccines - tOPV vs mOPV vs bOPV, with an IPV vs fIPV comparison table
  4. Global Eradication Measures - GPEI strategies plus a current status table (WPV1/2/3 and cVDPV)
Formatted with styled headings, color-coded tables, and source citations at the bottom.
This is a shared conversation. Sign in to Orris to start your own chat.